omniture

Tianyin Pharmaceutical Co., Inc. to Begin Trading on the American Stock Exchange on October 1, 2008

2008-10-01 18:03 1179

New Ticker ‘TPI’

CHENGDU, China, Oct. 1 /Xinhua-PRNewswire/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP - News), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that its common stock will begin trading on the American Stock Exchange (the "AMEX") under the ticker "TPI" at market open on Wednesday, October 1, 2008.

"Moving to the AMEX is a landmark for our Company. We expect that trading on the AMEX will elevate our Company’s standing within the international business community, as well as our visibility among the investment community," Dr. Jiang, Chairman and CEO of Tianyin commented. "I would like to thank both Tripoint Capital Advisors, the financial advisor for Tianyin Pharmaceuticals, and CMARK Capital, Tripoint’s partner in China, for being instrumental with the transition and activities since our Company became public."

The AMEX Panel’s approval is contingent upon the Company being in direct compliance with the Alternative Listing Standards at the time the Company’s common shares begin trading on the AMEX, and may be rescinded if the Company is not in compliance with such standards. Once Tianyin’s common shares commence trading on the AMEX, the Company will enjoy all of the same privileges and be subject to all of the same regulations as any other company whose shares are listed on the AMEX, regardless of the Listing Standard used to determine the Company’s eligibility.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 48 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,384 employees. Tianyin achieved revenue of $33.5 million and net income of $6 million in FY2008 ending June 30, 2008. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.

Source: Tianyin Pharmaceutical (TYNP)
Related Stocks:
NYSE:TPI
collection